BusinessRecent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian CancerBy Nasdaq OMXFeb 9, 2017, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXDec 6, 2016, 9:05 PM UTC
BusinessNew Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals’ PS-Targeting Antibodies in a Preclinical Melanoma ModelBy Nasdaq OMXNov 14, 2016, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXSep 21, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXSep 6, 2016, 8:05 PM UTC
BusinessPeregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016By Nasdaq OMXSep 1, 2016, 8:05 PM UTC
BusinessPreclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXApr 20, 2016, 12:05 PM UTC
